To discern whether this elevation in protein levels resulted from increased mRNA synthesis or a post-translational mechanism, we conducted LHPP protein degradation half-life assays in prostate cancer cells treated with Panobinostat (Fig. 6H and Fig. S8G). The gene discussed is LHPP; the disease is prostate cancer.